# [Amended]
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Final rule.
**SUMMARY:**
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) for fomepizole solution for injection from Jazz Pharmaceuticals, Inc., to Paladin Labs (USA), Inc.
**DATES:**
This rule is effective June 5, 2009.
**FOR FURTHER INFORMATION CONTACT:**
David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8307, e-mail: *[email protected]* .
**SUPPLEMENTARY INFORMATION:**
Jazz Pharmaceuticals, Inc., 3180 Porter Dr., Palo Alto, CA 94304, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141-075 for ANTIZOL-VET (fomepizole) to Paladin Labs (USA), Inc., 160 Greentree Dr., suite 101, Dover, DE 19904. Accordingly, the agency is amending the regulations in 21 CFR 522.1004 to reflect the transfer of ownership.
Following these changes of sponsorship, Jazz Pharmaceuticals, Inc., is no longer the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for this sponsor.
In addition, Paladin Labs (USA), Inc., is not currently listed in the animal drug regulations as a sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to add entries for this sponsor.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
**List of Subjects**
Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.
Animal drugs.
**21 CFR Part 510,522**
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:
**21 CFR Part 510**
**PART 510—NEW ANIMAL DRUGS**
1. The authority citation for 21 CFR part 510 continues to read as follows
**Authority:**
21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.
**21 CFR Part 510**
2. In § 510.600, in the table in paragraph (c)(1) remove the entry for “Jazz Pharmaceuticals, Inc.” and alphabetically add a new entry for “Paladin Labs, Inc.”; and in the table in paragraph (c)(2) remove the entry for “068727” and numerically add a new entry for “046129” to read as follows:
§ 510.600
(c) * * *
(1) * * *
| Firm name and address | Drug labeler code |
| --- | --- |
| * * * * * | |
| Paladin Labs (USA), Inc., 160 Greentree Dr., suite 101, Dover, DE 19904 | 046129 |
| * * * * * | |
(2) * * *
| Drug labeler code | Firm name and address |
| --- | --- |
| * * * * * | |
| 046129 | Paladin Labs (USA), Inc., 160 Greentree Dr., suite 101, Dover, DE 19904 |
| * * * * * | |
**21 CFR Part 522**
**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**
3. The authority citation for 21 CFR part 522 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
**21 CFR Part 522**
§ 522.1004
4. In paragraph (b) of § 522.1004, remove “068727” and add in its place “046129”.
Dated: June 1, 2009.
Bernadette Dunham,
Director, Center for Veterinary Medicine.